Each year, approximately 177,000 adults aged 65 and older are hospitalized in the United States due to RSV, and an estimated ...

Arexvy and Abrysvo are approved to prevent RSV-associated lower respiratory tract disease in adults aged 50 to 59 and 18 to ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

Its symptoms are similar to those of the common ... Currently, the CDC recommends that adults ages 75 years and older receive the adult RSV vaccine. It also recommends RSV vaccination for adults ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...

“With its vote to expand adult RSV vaccination recommendations, ACIP has taken an important step toward protecting individuals aged 50 to 59 who have underlying medical conditions that increase ...